Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS

British Journal of Haematology

Volumn 135, Issue 3, 2006, Pages 355-357

  Czibere, Akos ^a,b   Prall, Wolf C ^a,b   Zerbini, Luiz F ^b   Jäger, Markus ^a   Kobbe, Guido ^a   Knipp, Sabine ^a   Libermann, Towia A ^b   Haas, Rainer ^a   Aivado, Manuel ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute myeloid leukaemia; Apoptosis; c Jun NH2 terminal kinase; Exisulind; Myelodysplastic syndrome

Indexed keywords

CD34 ANTIGEN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SULINDAC SULFONE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL LINE; CELL VIABILITY; CLINICAL ARTICLE; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL; TREATMENT PLANNING;

ACUTE DISEASE; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; STEM CELLS; SULINDAC;

EID: 33749235503     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06298.x     Document Type: Article

References (12)

1. Aivado, M., Rong, A., Germing, U., Gattermann, N., Kobbe, G., Rieth, C., Haas, R. & Aul, C. (2000) Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. British Journal of Haematology, 110, 884-886.
2. Braun, T., Carvalho, G., Coquelle, A., Vozenin, M.C., Lepelley, P., Hirsch, F., Kiladjian, J.J., Ribrag, V., Fenaux, P. & Kroemer, G. (2006) NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood, 107, 1156-1165.
3. Czibere, A., Prall, W.C., Zerbini, L.F., Grall, F., Craigie, E.C., Ulrich, S.D., Giagounidis, A.A., Haas, R., Libermann, T.A. & Aivado, M. (2005) The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome. Cell Cycle, 6, 812-817.
4. Germing, U., Hildebrandt, B., Pfeilstocker, M., Nosslinger, T., Valent, P., Fonatsch, C., Lubbert, M., Haase, D., Steidl, C., Krieger, O., Stauder, R., Giagounidis, A.A., Strupp, C., Kundgen, A., Mueller, T., Haas, R., Gattermann, N. & Aul, C. (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia, 19, 2223-2231.
5. Greenberg, A. (1998) Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leukaemia Research, 22, 1123-1136.
6. Kanter-Lewensohn, L., Hellstrom-Lindberg, E., Kock, Y., Elmhorn-Rosenborg, A. & Ost, A. (1996) Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. European Journal of Haematology, 56, 124-129.
7. List, A., Beran, M., DiPersio, J., Slack, J., Vey, N., Rosenfeld, CS. & Greenberg, P. (2003) Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia, 17, 1499-1507.
8. Ray, G.F., Lanman, R.C., Fu, C.J., Paranak, N.S., Pamukcu, R. & Wheeler, S.C. (1995) Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. Journal of Pharmaceutical and Biomedical Analysis, 14, 213-220.
9. Thompson, W.J., Piazza, G.A., Li, H., Liu, L., Fetter, J., Zhu, B., Sperl, G., Ahnen, D. & Pamukcu, R. (2001) Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Research, 60, 3338-3342.
10. de Witte, T., Suciu, S., Verhoef, G., Labar, B., Archimbaud, E., Aul, C., Selleslag, D., Ferrant, A., Wijermans, P., Mandelli, F., Amadori, S., Jehn, U., Muus, P., Boogaerts, M., Zittoun, R., Gratwohl, A., Zwierzina, H., Hagemeijer, A. & Willemze, R. (2001) Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood, 98, 2326-2331.
11. Yamamoto, Y. & Gaynor, R.B. (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. Journal of Clinical Investigations, 107, 135-142.
12. Zerbini, L.F., Wang, Y., Czibere, A., Correa, R.G., Cho, J.Y., Ijiri, K., Wei, W., Joseph, M., Gu, X., Grall, F., Goldring, M.B., Zhou, J.R. & Libermann, T.A. (2004) NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proceedings of the National Academy of Science of the United States of America, 101, 13618-13623.